Here is another article with a substantive Cabo mention. Appropriately it scales Cabo in after Abi, MDV, and Alpharadin. It is a good indicator of the expectation of the clinical community, which is a few steps in advance of the financial community. Dr. Raghavan is an outspoken and influential ODAC member so his interest in Cabo is a plus.
Prostate Cancer: What did we learn from the 2012 Annual Scientific Meeting of ASCO?
From the article:
Another avenue of progress has been the identification of other molecular pathways in prostate tumorigenesis that have led to the discovery of novel therapeutic targets. MET is a receptor tyrosine kinase associated with oncogenic signaling that is expressed in prostate cancer and bone metastasis and is negatively regulated by androgen signaling.[28,29] Inhibition of MET activity has proven effective in murine xenograft prostate cancer models. Cabozantinib (XL-184) is a novel multi–tyrosine-kinase inhibitor with strong activity against MET and vascular endothelial growth factor (VEGF receptor) 2. A randomized phase II study of cabozantinib in patients with mCRPC initially reported at ASCO last year was prematurely unblinded based on significant clinical activity. A total of 86% of patients with lesions evaluable on bone scan demonstrated complete or partial resolution of skeletal lesions. In a study of an expanded nonrandomized cohort of 93 patients previously treated with docetaxel, reported this year, 60% of patients demonstrated a partial response on bone scan, and 46% of patients had reduced narcotic requirements following treatment with cabozantinib. In 59 patients with ≥ 5 circulating tumor cells (CTCs) prior to therapy, 39% converted to